NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy

The funds will be used to accelerate commercial growth and to pursue expanded indications for the RNS System, the companys innovative technology for refractory focal epilepsy.